Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents. 2013

Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar, Mohali, Punjab 160062, India.

Based on known heterocyclic topoisomerase II inhibitors and anticancer agents, various indenoindolone derivatives were predicted as potential topoisomerase II-inhibiting anticancer agents. They are hydrazones, (thio)semicarbazones, and oximes of indenoindolones, and indenoindolols. These derivatives with suitable substitutions exhibited potent specific inhibition of human DNA TopoIIα while not showing inhibition of topoisomerase I and DNA intercalation, despite the fact that parent indenoindolones are known poor/moderate inhibitors of topoisomerase II. The potent topoisomerase II inhibitor indenoindolone derivatives exhibited good anticancer activities compared to etoposide and 5-fluorouracil, and relatively low toxicity to normal cells. These derivatizations of indenoindolones were found to result in enhancement of anticancer activities.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D059005 Topoisomerase II Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. DNA Gyrase Inhibitor,DNA Topoisomerase II Inhibitor,Topoisomerase 2 Inhibitors,Topoisomerase II Inhibitor,DNA Gyrase Inhibitors,DNA Topoisomerase II Inhibitors,DNA Type 2 Topoisomerase Inhibitors,Gyrase Inhibitor, DNA,Gyrase Inhibitors, DNA,II Inhibitor, Topoisomerase,Inhibitor, DNA Gyrase,Inhibitor, Topoisomerase II,Inhibitors, DNA Gyrase,Inhibitors, Topoisomerase 2,Inhibitors, Topoisomerase II

Related Publications

Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
January 2021, Bioinformation,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
January 2002, Journal of medicinal chemistry,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
December 2023, Journal of enzyme inhibition and medicinal chemistry,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
January 2023, International journal of molecular sciences,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
December 2016, ACS medicinal chemistry letters,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
May 2009, Anti-cancer agents in medicinal chemistry,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
October 2020, Pharmacological reports : PR,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
December 2020, Journal of enzyme inhibition and medicinal chemistry,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
August 2013, Expert opinion on therapeutic patents,
Maneesh Kashyap, and Somnath Kandekar, and Ashish T Baviskar, and Dipon Das, and Ranjan Preet, and Purusottam Mohapatra, and Shakti Ranjan Satapathy, and Sumit Siddharth, and Sankar K Guchhait, and Chanakya N Kundu, and Uttam C Banerjee
July 2023, European journal of medicinal chemistry,
Copied contents to your clipboard!